Adrenoleukodystrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, by DelveInsight | Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Adrenoleukodystrophy pipeline constitutes 10+ key companies continuously working towards developing 11+ Adrenoleukodystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Adrenoleukodystrophy Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adrenoleukodystrophy Market.

The Adrenoleukodystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Adrenoleukodystrophy Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Adrenoleukodystrophy treatment therapies with a considerable amount of success over the years.

*
Adrenoleukodystrophy companies working in the treatment market are Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others, are developing therapies for the Adrenoleukodystrophy treatment

*
Emerging Adrenoleukodystrophy therapies such as - ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others are expected to have a significant impact on the Adrenoleukodystrophy market in the coming years.

Adrenoleukodystrophy Overview

Adrenoleukodystrophy (ALD) is a rare genetic disorder that affects the adrenal glands, the nervous system, and the myelin sheath of nerve cells in the brain. It primarily affects males and is caused by mutations in the ABCD1 gene located on the X chromosome.

Get a Free Sample PDF Report to know more about Adrenoleukodystrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight [https://www.delveinsight.com/report-store/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Adrenoleukodystrophy Drugs Under Different Phases of Clinical Development Include:

*
ABX-002: Autobahn Therapeutics

*
VK0214: Viking Therapeutics

*
SBT101: SwanBio Therapeutics

*
PXL065: Poxel SA

*
PXL770: Poxel SA

*
Leriglitazone : Minoryx Therapeutics

*
OP101 : Orpheris

*
Leriglitazone (MIN102): Minoryx Therapeutics

Route of Administration

Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Molecule Type

Products have been categorized under various Molecule types, such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Adrenoleukodystrophy Pipeline Therapeutics Assessment

*
Adrenoleukodystrophy Assessment by Product Type

*
Adrenoleukodystrophy By Stage and Product Type

*
Adrenoleukodystrophy Assessment by Route of Administration

*
Adrenoleukodystrophy By Stage and Route of Administration

*
Adrenoleukodystrophy Assessment by Molecule Type

*
Adrenoleukodystrophy by Stage and Molecule Type

DelveInsight's Adrenoleukodystrophy Report covers around 11+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Adrenoleukodystrophy product details are provided in the report. Download the Adrenoleukodystrophy pipeline report to learn more about the emerging Adrenoleukodystrophy therapies [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Adrenoleukodystrophy Therapeutics Market include:

Key companies developing therapies for Adrenoleukodystrophy are - AstraZeneca, Cipla Inc., Abbott, Bayer AG, Merck KGaA, GlaxoSmithKline plc, agtc, bluebird bio, MINORYX THERAPEUTICS SL, SwanBio Therapeutics, Inc., Viking Therapeutics, Novartis AG, Sanofi, Pfizer Inc., Sumitomo Corporation, Johnson & Johnson Private Limited, and others.

Adrenoleukodystrophy Pipeline Analysis:

The Adrenoleukodystrophy pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Adrenoleukodystrophy with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adrenoleukodystrophy Treatment.

*
Adrenoleukodystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Adrenoleukodystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adrenoleukodystrophy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Adrenoleukodystrophy drugs and therapies [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Adrenoleukodystrophy Pipeline Market Drivers

*
Increasing awareness towards genetic diseases coupled with genetic counseling, rise in the number of R&D activities are some of the important factors that are fueling the Adrenoleukodystrophy Market.

Adrenoleukodystrophy Pipeline Market Barriers

*
However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Adrenoleukodystrophy Market growth.

Scope of Adrenoleukodystrophy Pipeline Drug Insight

*
Coverage: Global

*
Key Adrenoleukodystrophy Companies: Autobahn Therapeutics, Viking Therapeutics, SwanBio Therapeutics, Poxel SA, Minoryx Therapeutics, and others

*
Key Adrenoleukodystrophy Therapies: ABX-002, VK0214, SBT101, PXL065, PXL770, Leriglitazone (MIN102), and others

*
Adrenoleukodystrophy Therapeutic Assessment: Adrenoleukodystrophy current marketed and Adrenoleukodystrophy emerging therapies

*
Adrenoleukodystrophy Market Dynamics: Adrenoleukodystrophy market drivers and Adrenoleukodystrophy market barriers

Request for Sample PDF Report for Adrenoleukodystrophy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/adrenoleukodystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Adrenoleukodystrophy Report Introduction

2

Adrenoleukodystrophy Executive Summary

3

Adrenoleukodystrophy Overview

4

Adrenoleukodystrophy- Analytical Perspective In-depth Commercial Assessment

5

Adrenoleukodystrophy Pipeline Therapeutics

6

Adrenoleukodystrophy Late Stage Products (Phase II/III)

7

Adrenoleukodystrophy Mid Stage Products (Phase II)

8

Adrenoleukodystrophy Early Stage Products (Phase I)

9

Adrenoleukodystrophy Preclinical Stage Products

10

Adrenoleukodystrophy Therapeutics Assessment

11

Adrenoleukodystrophy Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Adrenoleukodystrophy Key Companies

14

Adrenoleukodystrophy Key Products

15

Adrenoleukodystrophy Unmet Needs

16

Adrenoleukodystrophy Market Drivers and Barriers

17

Adrenoleukodystrophy Future Perspectives and Conclusion

18

Adrenoleukodystrophy Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=adrenoleukodystrophy-pipeline-update-2024-fda-approvals-therapeutic-advancements-by-delveinsight-autobahn-therapeutics-viking-therapeutics-swanbio-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.